CHEMOMAB THERAPEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6399 USD | -2.90% |
|
-5.90% | +25.47% |
| 10/04 | Transcript : Chemomab Therapeutics Ltd. - Special Call | |
| 07/03 | Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 78.67 | 36.88 | 6.029 | 9.09 | - | - |
| Enterprise Value (EV) 1 | 78.67 | 36.88 | 6.029 | 9.09 | 9.09 | 9.09 |
| P/E ratio | -115 x | -26.4 x | -4.95 x | -10.7 x | -8.53 x | -8.53 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,401 | 11,526 | 11,821 | 14,205 | - | - |
| Reference price 2 | 6.900 | 3.200 | 0.5100 | 0.6399 | 0.6399 | 0.6399 |
| Announcement Date | 09/03/22 | 21/02/23 | 07/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -12.37 | -28.53 | -25.46 | -15.89 | -22.34 | -23.42 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -12.48 | -28.18 | -24.22 | -15.5 | -27.35 | -27.95 |
| Net income 1 | -5.951 | -12.48 | -27.65 | -24.22 | -15.69 | -22.04 | -23.42 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | - | -0.0600 | -0.1210 | -0.1030 | -0.0600 | -0.0750 | -0.0750 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 19/03/21 | 09/03/22 | 21/02/23 | 07/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.891 | -5.024 | -5.32 | -6.254 | -8.317 | -8.642 | -9.049 | -8.195 | -4.367 | -3.848 | -3.916 | -3.942 | -4 | -4.034 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.968 | -5.036 | -5.104 | -6.734 | -8.08 | -8.262 | -8.732 | -7.936 | -4.136 | -3.417 | -3.75 | -3.75 | -4 | -4 |
| Net income 1 | -2.968 | -5.036 | -5.104 | -6.19 | -8.08 | -8.272 | -8.753 | -7.97 | -4.081 | -3.417 | -3.816 | -3.842 | -4 | -4.034 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0130 | -0.0220 | -0.0220 | -0.0270 | -0.0350 | -0.0360 | -0.0400 | -0.0360 | -0.0170 | -0.0130 | -0.0150 | -0.0150 | -0.0150 | -0.0150 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/21 | 09/03/22 | 12/05/22 | 12/08/22 | 10/11/22 | 21/02/23 | 11/05/23 | 14/08/23 | 09/11/23 | 07/03/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 0.24 | 0.07 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 19/03/21 | 09/03/22 | 21/02/23 | 07/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6399
USD
Average target price
7
USD
Spread / Average Target
+993.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.47% | 9.09M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CMMB Stock
- Financials Chemomab Therapeutics Ltd.
